Quantamatrix

1 known investors

QuantaMatrix develops dRAST, a rapid antimicrobial susceptibility testing (AST) system that provides fast results to guide targeted antimicrobial therapy for sepsis patients. The product aims to reduce inappropriate antibiotic use and antimicrobial resistance in clinical diagnostics.